Molecular imaging represents a bridge between basic and clinical neuroscience observations and provides many opportunities for translation and identifying mechanisms that may inform prevention and intervention strategies in late-life depression (LLD). Substantial advances in instrumentation and radiotracer chemistry have resulted in improved sensitivity and spatial resolution and the ability to study in vivo an increasing number of neurotransmitters, neuromodulators, and, importantly, neuropathological processes. Molecular brain imaging studies in LLD will be reviewed, with a primary focus on positron emission tomography. Future directions for the field of molecular imaging in LLD will be discussed, including integrating molecular imaging with genetic, neuropsychiatric, and cognitive outcomes and multimodality neuroimaging.
PhelpsMMazziottaJSchelbertH, eds. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press; 1986:237–286.
2.
BaileyDTownsendDValkPMaiseyM. Positron emission tomography. Basic Science. United States: Springer; 2005.
3.
ShaoXHoareauRHockleyBG. Highlighting the versatility of the tracerlab synthesis modules. part 1: fully automated production of [F]labelled radiopharmaceuticals using a tracerlab FX(FN). J Labelled Comp Radiopharm. 2011;54(6):292–307.
4.
FerrisSHde LeonMJWolfAP. Positron emission tomography in dementia. Adv Neurol. 1983;38:123–129.
5.
GiovacchiniGSquitieriFEsmaeilzadehMMilanoAMansiLCiarmielloA. PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. J Cell Physiol. 2011;226(4):948–961.
6.
KumarA. Functional brain imaging in late-life depression and dementia. J Clin Psychiatry. 1993;54suppl:21–25.
7.
BuchsbaumMSIngvarDHKesslerR. Cerebral glucography with positron tomography. use in normal subjects and in patients with schizophrenia. Arch Gen Psychiatry. 1982;39(3):251–259.
8.
PhelpsMEMazziottaJCBaxterLGernerR. Positron emission tomographic study of affective disorders: Problems and strategies. Ann Neurol. 1984;15suppl:S149–S156.
9.
BaxterLRJrPhelpsMEMazziottaJCGuzeBHSchwartzJMSelinCE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987;44(3):211–218.
10.
WagnerHNJrBurnsHDDannalsRF. Imaging dopamine receptors in the human brain by positron tomography. Science. 1983;221(4617):1264–1266.
11.
ArnettCDWolfAPShiueCY. Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. J Nucl Med. 1986;27(12):1878–1882.
12.
BooijJvan AmelsvoortT. Imaging as tool to investigate psychoses and antipsychotics. Handb Exp Pharmacol. 2012;(212):299–337.
13.
WongDFTauscherJGrunderG. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 2009;34(1):187–203.
14.
SacherJSmithG. Molecular imaging of depression. In: TuretskyBShentonM, eds. Imaging Neuropsychiatric Disorders, New York: Cambridge University Press; 2011:170–196.
15.
ChauveauFBoutinHVan CampNDolleFTavitianB. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304–2319.
16.
MathisCAWangYHoltDPHuangGFDebnathMLKlunkWE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46(13):2740–2754.
17.
ChienDTBahriSSzardeningsAK. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457–468.
18.
NealKLShakerdgeNBHouSS. Development and screening of contrast agents for in vivo imaging of parkinson's disease. Mol Imaging Biol. 2013;15(5):585–595.
19.
WienhardK. Measurement of glucose consumption using [(18)F]fluorodeoxyglucose. Methods. 2002;27(3):218–225.
20.
TownsendDW. Multimodality imaging of structure and function. Phys Med Biol. 2008;53(4):R1–R39.
21.
WehrlHFSauterAWJudenhoferMSPichlerBJ. Combined PET/MR imaging--technology and applications. Technol Cancer Res Treat. 2010;9(1):5–20.
22.
RoussetOGCollinsDLRahmimAWongDF. Design and implementation of an automated partial volume correction in PET: Application to dopamine receptor quantification in the normal human striatum. J Nucl Med. 2008;49(7):1097–1106.
23.
ShidaharaMTsoumpasCHammersA. Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage. 2009;44(2):340–348.
24.
MontgomeryAJThielemansKMehtaMATurkheimerFMustafovicSGrasbyPM. Correction of head movement on PET studies: comparison of methods. J Nucl Med. 2006;47(12):1936–1944.
25.
RahmimADinelleKChengJC. Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging. 2008;27(8):1018–1033.
26.
MaybergHS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 2003;65:193–207.
27.
FitzgeraldPBLairdARMallerJDaskalakisZJ. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008;29(6):683–695.
28.
SavitzJBDrevetsWC. Neuroreceptor imaging in depression. Neurobiol Dis. 2013;52:49–65.
29.
KumarANewbergAAlaviABerlinJSmithRReivichM. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: A preliminary positron emission tomography study. Proc Natl Acad Sci U S A. 1993;90(15):7019–7023.
30.
NoblerMSRooseSPProhovnikI. Regional cerebral blood flow in mood disorders, V.: Effects of antidepressant medication in late-life depression. Am J Geriatr Psychiatry. 2000;8(4):289–296.
31.
SmithGSReynoldsCFPollockB. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry. 1999;156(5):683–689.
32.
SmithGSKramerEHermannCR. Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. Am J Geriatr Psychiatry. 2002;10(6):715–723.
33.
SmithGSReynoldsCFIIIHouckPR. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry Res. 2009;171(1):1–9.
34.
SmithGSKramerEMaY. The functional neuroanatomy of geriatric depression. Int J Geriatr Psychiatry. 2009;24(8):798–808.
35.
SmithGSReynoldsCFIIIHouckPR. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry. 2002;10(5):561–567.
36.
DiaconescuAOKramerEHermannC. Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression. Hum Brain Mapp. 2011;32(10):1677–1691.
37.
SmithGSWorkmanCIKramerE. The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. Am J Geriatr Psychiatry. 2011;19(1):53–63.
38.
BucknerRLSnyderAZShannonBJ. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709–7717.
39.
SchildkrautJJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509–522.
40.
LapinIPOxenkrugGF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969;1(7586):132–136.
41.
BrownASGershonS. Dopamine and depression. J Neural Transm Gen Sect. 1993;91(2-3):75–109.
42.
NestlerEJCarlezonWAJr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006;59(12):1151–1159.
43.
KlimekVSchenckJEHanHStockmeierCAOrdwayGA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry. 2002;52(7):740–748.
44.
BowdenCTheodorouAECheethamSC. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res. 1997;752(1-2):227–233.
45.
AgrenHReibringL. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry. 1994;27(1):2–6.
46.
MeyerJHKrugerSWilsonAA. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12(18):4121–4125.
47.
SuharaTNakayamaKInoueO. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl). 1992;106(1):14–18.
48.
CannonDMKlaverJMPeckSARallis VoakDEricksonKDrevetsWC. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology. 2009;34(5):1277–1287.
49.
KlimkeALarischRJanzAVosbergHMuller-GartnerHWGaebelW. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 1999;90(2):91–101.
50.
ParseyRVOquendoMAZea-PonceY. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001;50(5):313–322.
51.
HirvonenJKarlssonHKajanderJ. Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl). 2008;197(4):581–590.
52.
MontgomeryAJStokesPKitamuraYGrasbyPM. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride. J Affect Disord. 2007;101(1-3):113–122.
53.
MeyerJHMcNeelyHESagratiS. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: An [11C]raclopride positron emission tomography study. Am J Psychiatry. 2006;163(9):1594–1602.
54.
AnandAVerhoeffPSenecaN. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000;157(7):1108–1114.
55.
VolkowNDGurRCWangGJ. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry. 1998;155(3):344–349.
56.
VolkowNDWangGJFowlerJS. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998;44(1):143–147.
57.
LavretskyHKumarA. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry. 2001;9(3):298–303.
58.
MannJJ. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 1999;21(2 suppl):99S–105S.
59.
OwensMJNemeroffCB. The serotonin transporter and depression. Depress Anxiety. 1998;8suppl 1:5–12.
60.
McKeithIGMarshallEFFerrierIN. 5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord. 1987;13(1):67–74.
61.
ArangoVErnsbergerPMarzukPM. Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry. 1990;47(11):1038–1047.
62.
StockmeierCAShapiroLADilleyGEKolliTNFriedmanLRajkowskaG. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci. 1998;18(18):7394–7401.
63.
ThomasAJHendriksenMPiggottM. A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimer's disease with and without depression. Neuropathol Appl Neurobiol. 2006;32(3):296–303.
64.
AgrenHReibringLHartvigP. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand. 1991;83(6):449–455.
65.
Rosa-NetoPDiksicMOkazawaH. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry. 2004;61(6):556–563.
66.
CannonDMIchiseMFrommSJ. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry. 2006;60(3):207–217.
67.
CannonDMIchiseMRollisD. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry. 2007;62(8):870–877.
68.
ReimoldMBatraAKnobelA. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: A [11C]DASB PET study. Mol Psychiatry. 2008;13(6):606–13, 557.
69.
MillerJMOquendoMAOgdenRTMannJJParseyRV. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res. 2008;42(14):1137–1144.
70.
ParseyRVKentJMOquendoMA. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry. 2006;59(9):821–828.
71.
BhagwagarZMurthyNSelvarajS. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry. 2007;164(12):1858–1865.
72.
MeyerJHHouleSSagratiS. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004;61(12):1271–1279.
MeyerJHWilsonAAGinovartN. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatry. 2001;158(11):1843–1849.
75.
SmithGSKahnASacherJ. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. Am J Geriatr Psychiatry. 2011;19(12):1016–1025.
76.
SmithGSKramerEHermannC. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry. 2009;66(3):259–266.
77.
DrevetsWCFrankEPriceJC. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46(10):1375–1387.
78.
SargentPAKjaerKHBenchCJ. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57(2):174–180.
79.
HirvonenJKarlssonHKajanderJ. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: An in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol. 2008;11(4):465–476.
80.
ParseyRVOquendoMAOgdenRT. Altered serotonin 1A binding in major depression: A [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59(2):106–113.
81.
ParseyRVOlvetDMOquendoMAHuangYYOgdenRTMannJJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006;31(8):1745–1749.
82.
Moses KolkoELPriceJCThaseME. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse. 2007;61(7):523–530.
83.
MeltzerCCPriceJCMathisCA. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004;29(12):2258–2265.
84.
BlierPDe MontignyCAzzaroAJ. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther. 1986;237(3):987–994.
85.
MeyerJHKapurSEisfeldB. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001;158(1):78–85.
86.
MeltzerCCPriceJCMathisCA. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry. 1999;156(12):1871–1878.
87.
BiverFWiklerDLotstraFDamhautPGoldmanSMendlewiczJ. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br J Psychiatry. 1997;171:444–448.
88.
ShelineYIMintunMABarchDMWilkinsCSnyderAZMoerleinSM. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology. 2004;29(12):2235–2241.
89.
MeyerJHKapurSHouleS. Prefrontal cortex 5-HT2 receptors in depression: An [18F]setoperone PET imaging study. Am J Psychiatry. 1999;156(7):1029–1034.
90.
BhagwagarZHinzRTaylorMFancySCowenPGrasbyP. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry. 2006;163(9):1580–1587.
91.
YathamLNLiddlePFDennieJ. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry. 1999;56(8):705–711.
92.
MorescoRMColomboCFazioF. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: a PET study. Neuroimage. 2000;12(4):452–465.
93.
MassouJMTrichardCAttar-LevyD. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl). 1997;133(1):99–101.
94.
CannonDMCarsonRENugentAC. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006;63(7):741–747.
95.
DrevetsWCZarateCAJrFureyML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013;73(12):1156–1163.
96.
ZarateCAJrSinghJBCarlsonPJ. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.
97.
KendellSFKrystalJHSanacoraG. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets. 2005;9(1):153–168.
98.
HaslerGvan der VeenJWTumonisTMeyersNShenJDrevetsWC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193–200.
99.
DeschwandenAKarolewiczBFeyissaAM. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry. 2011;168(7):727–734.
100.
Machado-VieiraRSalvadoreGDiazgranadosNZarateCAJr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009;123(2):143–150.
101.
BrambillaPPerezJBaraleFSchettiniGSoaresJC. GABAergic dysfunction in mood disorders. Mol Psychiatry. 2003;8(8):721–37, 715.
102.
ZarateCAJrDuJQuirozJ. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci. 2003;1003:273–291.
103.
KhundakarAMorrisCThomasAJ. The immunohistochemical examination of GABAergic interneuron markers in the dorsolateral prefrontal cortex of patients with late-life depression. Int Psychogeriatr. 2011;23(4):644–653.
104.
RichardsonJSMillerPSLemayJS. Mental dysfunction and the blockade of muscarinic receptors in the brains of the normal elderly. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):651–654.
105.
SweetRAHamiltonRLButtersMA. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology. 2004;29(12):2242–2250.
106.
TsopelasCStewartRSavvaGM. Neuropathological correlates of late-life depression in older people. Br J Psychiatry. 2011;198(2):109–114.
107.
KhundakarAAThomasAJ. Cellular morphometry in late-life depression: a review of postmortem studies [published online Septemeber 5, 2013]. Am J Geriatr Psychiatry. 2013.
108.
ButtersMAKlunkWEMathisCA. Imaging Alzheimer pathology in late-life depression with PET and pittsburgh compound-B. Alzheimer Dis Assoc Disord. 2008;22(3):261–268.
109.
MaranoCMWorkmanClLymanCH. Cortical beta-amyloid deposition in late-life depression. Am J Geriatr Psychiatry. 2013;21(3):127.
110.
KumarAKepeVBarrioJR. Protein binding in patients with late-life depression. Arch Gen Psychiatry. 2011;68(11):1143–1150.
111.
LavretskyHSiddarthPKepeV. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry. 2009;17(6):493–502.
112.
SmithGSGunning-DixonFMLotrichFETaylorWDEvansJD. Translational research in late-life mood disorders: Implications for future intervention and prevention research. Neuropsychopharmacology. 2007;32(9):1857–1875.
113.
ZhuCBBlakelyRDHewlettWA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology. 2006;31(10):2121–2131.
114.
LoprestiALMakerGLHoodSDDrummondPD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2013;48C:102–111.
115.
HannestadJDellagioiaNGallezotJD. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [(11)C]PBR28 PET study. Brain Behav Immun. 2013;33:131–138.
116.
ThomasAJO’BrienJTDavisS. Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry. 2002;59(9):785–792.
117.
PiersonMEAnderssonJNybergS. [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage. 2008;41(3):1075–1085.
118.
MarnerLGillingsNComleyRA. Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med. 2009;50(6):900–908.
119.
ParkerCAGunnRNRabinerEA. Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012;53(2):295–303.
120.
DingYSSinghalTPlaneta-WilsonB. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S, S)-[(11)C]O-methylreboxetine and HRRT. Synapse. 2010;64(1):30–38.
121.
MathewSJManjiHKCharneyDS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008;33(9):2080–2092.
122.
FureyMLDrevetsWC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–1129.
MillerAHMaleticVRaisonCL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–741.
125.
BrodneyMAJohnsonDESawant-BasakA. Identification of multiple 5-HT(4) partial agonist clinical candidates for the treatment of Alzheimer’s disease. J Med Chem. 2012;55(21):9240–9254.
126.
SteenslandPFredrikssonIHolstS. The monoamine stabilizer (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry. 2012;72(10):823–831.
127.
JorgeREMoserDJAcionLRobinsonRG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 2008;65(3):268–276.
